Alnylam Pharmaceuticals Inc (ALNY)

Add to Watchlists
Create an Alert
Quickflows
176.89 +4.64  +2.69% NASDAQ Jun 18, 20:00 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All ALNY News

News

View All Events

Events

Date Type Description
08/06/2021 Earnings Results Q2 2021 Earnings Results
08/06/2021 08:30 EST Earnings Calls Q2 2021 Earnings Call
04/29/2021 Earnings Results Q1 2021 Earnings Results
04/29/2021 08:30 EST Earnings Calls Q1 2021 Earnings Call
02/11/2021 Earnings Results Q4 2020 Earnings Results
02/11/2021 08:30 EST Earnings Calls Q4 2020 Earnings Call
11/05/2020 Earnings Results Q3 2020 Earnings Results
11/05/2020 08:30 EST Earnings Calls Q3 2020 Earnings Call
08/06/2020 Earnings Results Q2 2020 Earnings Results
08/06/2020 08:30 EST Earnings Calls Q2 2020 Earnings Call
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 570.94M
Total Expenses (TTM) 1.375B
Net Income (TTM) -876.35M

Balance Sheet View Statement

Total Assets (Quarterly) 3.255B
Total Liabilities (Quarterly) 2.329B
Shareholders Equity (Quarterly) 926.19M

Cash Flow Statement View Statement

Cash from Operations (TTM) -604.46M
Cash from Investing (TTM) -477.85M
Cash from Financing (TTM) 992.29M

Ratings & Reports

Advertisement
Edit

Profile

  • Description: Alnylam Pharmaceuticals Inc is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis and givosiran (Givlaari) for acute hepatic porphyria, Alnylam has several partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
  • URL: https://www.alnylam.com
  • Investor Relations URL: https://investors.alnylam.com
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Aug. 06, 2021
  • Last Earnings Release: Apr. 29, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 176.89
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
FIJYX Fidelity Advisor® Biotechnology Z 5.17%
FBT First Trust NYSE Arca Biotech ETF 3.87%
BBH VanEck Vectors Biotech ETF 3.11%
FBIOX Fidelity® Select Biotechnology 2.46%
VGHCX Vanguard Health Care Inv 2.28%
IBB iShares Nasdaq Biotechnology ETF 1.59%
FSPHX Fidelity® Select Health Care 1.23%
BMEZ BlackRock Health Sciences Trust II 1.18%
FGCKX Fidelity® Growth Company K 0.84%
XBI SPDR® S&P Biotech ETF 0.84%
FCGSX Fidelity® Series Growth Company 0.79%
XT iShares Exponential Technologies ETF 0.59%

Comparables

Edit
MRK Merck & Co Inc
BMY Bristol-Myers Squibb Co
BMRN Biomarin Pharmaceutical Inc
VRTX Vertex Pharmaceuticals Inc
AGIO Agios Pharmaceuticals Inc

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.